State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

State Street Corp raised its holdings in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 12.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 476,439 shares of the company’s stock after purchasing an additional 52,528 shares during the quarter. State Street Corp owned 1.07% of Werewolf Therapeutics worth $1,010,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. PFM Health Sciences LP grew its holdings in shares of Werewolf Therapeutics by 4.9% during the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after buying an additional 157,673 shares during the last quarter. Walleye Capital LLC lifted its position in Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after acquiring an additional 10,528 shares in the last quarter. SG Americas Securities LLC acquired a new position in Werewolf Therapeutics during the 3rd quarter valued at about $29,000. Point72 DIFC Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $34,000. Finally, Murchinson Ltd. purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth approximately $152,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Stock Up 5.4 %

Werewolf Therapeutics stock opened at $1.56 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market cap of $69.52 million, a PE ratio of -1.02 and a beta of 0.30. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $8.19. The firm’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $2.18.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.